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Abstract
Background: The family of A-kinase-anchoring proteins, AKAPs, constitutes a group of molecular scaffolds that act
to catalyze dynamic interactions of protein kinase A, protein kinase C, tyrosine kinases, G-protein-coupled receptors
and ion channels. AKAP5 (MW ~47 kDa) and AKAP12 (MW ~191 kDa) homo-oligomerize, but whether or not such
AKAPs can hetero-oligomerize into supermolecular scaffolds of increased complexity is unknown.
Results: Affinity chromatography using immobilized AKAPs as “bait” demonstrates unequivocally that AKAP5 and
AKAP12 do form minimally hetero-dimers. Steric-exclusion chromatography of AKAP5 and AKAP12 mixtures
revealed the existence of very large, supermolecular complexes containing both AKAPs. Docking of AKAP5 to
AKAP12 was increased 4-fold by beta-adrenergic agonist stimulation. Overexpression of AKAP12 was found to
potentiate AKAP5-mediated Erk1/2 activation in response to stimulation with beta-adrenergic agonist.
Conclusion: AKAP5 and AKAP12 are capable of forming hetero-oligomeric supermolecular complexes that
influence AKAP locale and function.
Keywords: AKAP5, AKAP12, gravin, SSECKS, protein kinase A, scaffold, beta-adrenergic receptor, homo-oligomer,
hetero-oligomer, oligomerization
Background
Scaffold proteins have emerged as essential elements of
cell signaling, providing docking sites at which protein
kinases, phosphoprotein phosphatases, G-protein-linked
receptors/ion channels can interact. An important sub-
set of scaffold molecules possesses a docking site for the
regulatory subunits (i.e., RI/RII) of cyclic AMP-depen-
dent protein kinase A (PKA, A-kinase), termed A-
kinase-anchoring proteins (AKAP) intimately involved in
cellular signaling [1-4]. AKAPs dock PKA, acting as well
as molecular “tool boxes” reflecting multivalency and
the ability to dock other signaling proteins, including a
full range of protein kinases (e.g., PKA, protein kinase C
[5-8], and the tyrosine kinases [9]), phosphoprotein
phosphatases (e.g., protein phosphatase 2B (PP2B)
[5,10], cyclic AMP phosphodiesterases (e.g., PDE4)
[11-14], adaptor molecules [11,13,15,16], ion channels
[17-20], and members of the superfamily of G protein-
coupled receptors (GPCR) [21-23]. AKAP5 and
AKAP12, for example, associates with the prototypic
GPCR, the b2-adrenergic receptor [23]. To what extent
these AKAPs associate with other members of the
GPCR superfamily is not known. The AKAPs that do
dock GPCRs have been one of the major foci of AKAP
research [23-26].
In 2003 we first reported the oligomerization of
AKAPs [27], noting that AKAP12 oligomers were SDS-
resistant and could only be disassembled in the presence
of a chaotropic agent, such as 8 M urea. More recently,
oligomerization has been reported for AKAP5 [28,29],
although AKAP5 oligomers are not SDS-resistant.
AKAP5 oligomers display MW on wide-bore steric
exclusion chromatography indicative of homo-oligomers
of dimers and tetramers [28]. That both AKAP5 and
AKAP 12 were capable of forming large, homo-oligo-
meric complexes (e.g., dimers and tetramers) provoked
our interest in interrogating the exciting possibility that
AKAP scaffolds might form hetero-oligomers, capable of
extending the functional repertoire of docking proteins
assembled by each [28]. Herein, we probe further these
two members of the class of GPCR-associated AKAPs
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able of forming AKAP hetero-oligomers. Both AKAP5
and AKAP12 are predicted to be more than 85%
natively unordered [10], based upon primary sequence
information alone. The current work is the first to
report that both AKAP5 and AKAP12 form hetero-oli-
gomers, i.e., large supermolecular assemblies of AKAP5-
AKAP12 that are functionally significant. Thus AKAP-
AKAP docking adds a new dimension on how members
of this class of scaffold molecules function in cell
signaling.
Materials and methods
Antibodies
Mouse anti-AKAP5, anti-pERK monoclonal antibody, rab-
bit anti-ERK, goat anti-mouse IgG-HRP, and goat anti-rat
IgG-HRP were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Mouse anti-AKAP12 monoclonal anti-
body was purchased from Abcam (Cambridge, MA).
Mouse anti-GFP, Rat anti-HA antibody and HA-agarose
beads are products of Roche (Indianapolis, IN).
Cell lines
The human epithelial carcinoma cell line A431 [30,31]
and human embryonic kidney cell line HEK293
[14,23,24,32] were obtained from ATCC (Bethesda, MD)
and cultured in Dulbecco’s modified Eagle’sm e d i u m
(DMEM) containing 10% fetal bovine serum in a humi-
dified atmosphere containing 5% CO2 at 37°C. Conflu-
ent cells were treated with 10 μM isoproterenol (Iso) in
DMEM, for indicated times.
Plasmids and transfection
pcDNA3.1 vector carrying HA-tagged AKAP12, HA-
AKAP12 (1-362), HA-AKAP12 (1-652), HA-AKAP12
(554-938), HA-AKAP12 (1-938), and HA-AKAP12 (840-
1782) were constructed as described previously [27].
pCMV-HA vector carrying AKAP5, His-tagged AKAP12
(840-1782), AKAP12(1-840) and AKAP5 were con-
structed as described previously[28]. A431 or HEK293
cells were transfected with plasmid DNA using Express-
Fect
® (Denville Scientific, Metuchen, NJ), according to
the manufacturer’s instructions. A431 cells stably expres-
sing AKAP79-GFP or AKAP12-GFP were established
using G418 at 400 μg/ml and maintained at 100 μg/ml.
Purification of His-tagged AKAP5 and AKAP12
His-tagged proteins expressed in E. coli were purified by
using Ni-NTA matrix (Qiagen, Valencia, CA), according
to the manufacturer’s protocol.
Crosslinking of AKAPs to CNBr-activated Sepharose 4B
Purified His-tagged AKAP12 (1-840), His-tagged-
AKAP12 (840-1782) were cross-linked to CNBr-
activated Sepharose 4B (GE Healthcare), as described in
the product manual.
Steric-exclusion chromatography of AKAP supermolecular
complexes
Purified His-tagged AKAP5 or AKAP12 (or both) was
(were) applied to the Sephacryl-400 gel filtration column
(HiPrep Sephacryl S-400 High resolution 16/60, GE
Healthcare) making use of a fast-performance liquid
chromatography system AKTA (GE Healthcare), pre-
equilibrated with PBS supplemented with 0.01% NaN3.
Sample (1.0 ml) fractions were collected. Each fraction
was analyzed by SDS-PAGE and immunoblotting. Pro-
tein was detected in the flow-cell by measuring absor-
bance at A280. The column was calibrated with gel
filtration calibration kit HMW (GE Healthcare).
Pull-down assay
T y p i c a l l ya2 0μl of AKAP12 fragment (840-1782)-
Sepharose 4B or AKAP12 (1-840)-Sepharose 4B beads
were incubated with purified His-tagged AKAP5 or
GST-G3BP1 in phosphate buffered saline (PBS) contain-
ing 1% Triton X-100 and 1 mg/ml BSA at 4°C for 1 h.
Pellets were washed with PBS containing 1% Triton X-
100 three times and boiled with 30 μl Laemmli buffer at
95°C for 5 min. The supernatant was loaded onto a 7%
polyacrylamide gel and subjected to sodium dodecylsul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE).
AKAP5 was detected by immunoblotting with anti-
AKAP5 antibody.
Immunoprecipitation and immunoblotting
Cells were harvested in a lysis buffer containing 20 mM
T r i s - H C l ,p H7 . 4 ,1 %N o n i d e tP - 4 0 ,2m Ms o d i u m
orthovanadate, 150 mM NaCl, 5 mM EDTA, 50 mM
NaF, 40 mM sodium pyrophosphate, 50 mM KH2PO4,
10 mM sodium molybdate, and a cocktail of protease
inhibitors (Complete Protease Inhibitor Cocktail tablet,
Roche, Nutley, NJ). After centrifugation at 10,000 × g
for 15 min, the protein concentration of the supernatant
was determined using the Bradford reagent. One mg of
protein was incubated with specific primary antibody for
4 h at 4°C, then 20 μl of protein A/G agarose was added
and the mixture was incubated for 2 h on a rolling
mixer. Immune complexes were collected and washed
three times with PBS containing 1% Triton X-100, and
thereafter boiled for 5 min at 95°C in 30 μl of Laemmli
buffer. The supernatant was subjected to SDS-PAGE
and the resolved proteins were transferred to a PVDF
membrane. The blot was probed with specific antibo-
dies. The immune complexes on the blots were made
visible by staining with a horseradish peroxidase-conju-
gated secondary antibody in combination with the che-
miluminescence reagent, followed by a brief
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Aldrich, St. Louis, MO).
Assay of b2-adrenergic receptor recycling
Using radioligand equilibrium binding assays with a cell-
impermeant, tritiated antagonist ([
3H]CGP-12177).
HEK293 cells stably expressing b2-AR-GFP or A431cells
were treated with isoproterenol for 30 min then washed
free of agonist and allowed to recover for 120 min. The
cells next were washed with ice-cold DMEM, and then
changed to ice-cold Dulbecco’s modified Eagle’s medium
containing 20 mM HEPES, pH 7.4, and the hydrophilic,
membrane-impermeant b2-adrenergic antagonist [
3H]
CGP-12177 (10 nM). Non-specific binding was deter-
mined by adding 10 μM propranolol to the incubation
solution. Binding was performed at 4°C for 4 h [24-26].
The cells were then washed with ice-cold PBS and col-
lected with 1% SDS and 1% NP-40. The lysates were
counted by scintillation spectroscopy.
Results
AKAP5 and AKPA12 hetero-oligomerization: analysis by
affinity chromatography
The observations that both AKAP5 and AKAP12 were
capable of forming homodimers and homooligomers of
higher order stimulated us to ask whether AKAPs might
be able to assemble not only as homodimers/-oligomers,
but also as hetero-oligomers. We probed possible inter-
actions between these two GPCR-docking AKAPs using
several different approaches. The first approach
employed affinity chromatography in which AKAP12 (or
a large N-terminal or C-terminal fragment) was immo-
bilized to a solid matrix (i.e., chemically coupled to
Sepharose 4B beads) and used as “bait” for AKAP5. In
vitro binding assays making use of purified proteins
demonstrated that the full-length AKAP12 docks
AKAP5 (Figure 1A); N-terminal AKAP12 (1-840) and
C-terminal AKAP12 (840-1782) also display the ability
to dock AKAP5 (Figure 1A). At equivalence of deriva-
tized matrix, the C-terminal fragment of AKAP12
bound less AKAP5 than the N-terminal AKAP12 frag-
ment. Thus it appears that AKAP5 is capable of docking
to AKAP12 either N-terminally or C-terminally to the
much larger AKAP12. The matrix, absent bound either
full-length or N-terminal and C-terminal fragments of
AKAP12, retained no AKAP5. When an unrelated pro-
tein, GST-tagged G3BP1, was employed in place of
AKAP5 in this in vitro analysis, no G3BP1 was found
bound to AKAP12-derived matrices.
We next probed in vivo whether docking of AKAP5 to
full length AKAP12 was influenced by activation of the
A-kinase provoked via treating cells with the beta-adre-
nergic agonist isoproterenol. A431 cells co-expressing
both HA-tagged full-length AKAP5 and GFP-tagged
AKAP12 were employed. The cells expressing AKAP5
and AKAP12 were stimulated with 10 μM isoproterenol
for periods of 10 to 30 min (Figure 1B). Pull-downs of
HA-tagged AKAP5 were performed from whole-cell
lysates and the AKAP5 analyzed for bound AKAP12. In
the absence of stimulation, pull-downs of AKAP5
revealed some docking of full-length AKAP12 to
AKAP5 (Figure 1B). Following stimulation with b-adre-
nergic agonist, the amount of AKAP12 docking to
AKAP5 increased progressively over time. AKAP12
docking with AKAP5 increased up to 30 min post treat-
ment with isoproterenol, the latest time tested. At 30
min, beta-adrenergic agonist stimulated an increase in
the amount of AKAP12 docking to AKAP5 of 4-fold.
We ascertained if the process was dynamic, probing
reversibility of the AKAP5-AKAP12 binding once the
stimulated cells were washed free of b-adrenergic ago-
nist (Figure 1B). At 30 min of b-adrenergic agonist, the
bulk of b2-adrenergic receptors have been fully acti-
vated, desensitized, and internalized [16,24-26]. At 2 h
post wash-out, resensitization/recycling of b2-adrenergic
receptors, a process in which AKAP12 is essential
[17,24], has been completed [16,24-26]. Following the
two-hour wash-out of agonist, the amount of AKAP12
found associated with AKAP5 declined sharply to the
level close to the basal state. Thus AKAP12 docking to
AKAP5 is enhanced by stimulation of b-adrenergic
pathway and is dynamic, i.e., capable of reversal by ago-
nist wash-out and a 2 h period of recovery in vivo (Fig-
ure 1B). Control pull-downs conducted with IgG rather
than anti-HA antibody failed to reveal either bound
AKAP5 or bound AKAP12.
The ability of AKAP5 to dock to immobilized C-term-
inal fragment of AKAP12 (840-1782) in vitro (Figure
1A) stimulated further analysis of this docking (Figure
2A). Binding of AKAP5 to C-terminal AKAP12 was
assessed by sedimentation of the Sepharose beads to
which AKAP12 (840-1782) fragment was immobilized.
The conditions employed for the incubation of AKAP5
with C-terminal AKAP12 beads varied from 1 h at 37°C,
to overnight (17 h) and 1 h at 4°C. Purified AKAP5 dis-
plays robust docking to the C-terminal fragment of
AKAP12, under each of the conditions employed. The
analysis then was performed in vivo, testing AKAP5 and
AKAP12 docking properties under physiological condi-
tions. A431 cells stably expressing GFP-tagged AKAP5
were transiently transfected to express the HA-tagged
AKAP12 (840-1782) fragment (Figure 2B). Pull-downs
of HA-tagged AKAP12 (840-1782) performed from
whole-cell lysates were quantitative. AKAP5 was shown
to be capable of docking to the AKAP12 fragment in
the basal, “unstimulated” state. We probed if stimulating
the cells with the b-adrenergic agonist isoproterenol (10
μM) would alter the docking of AKAP5 to the AKAP12
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tagged AKAP12 fragment was pulled-down and AKAP5
docking probed. b-adrenergic stimulation did not
change the amount of the AKAP5 docking to the C-
terminal region of AKAP12 (Figure 2B). The amounts of
AKAP5 and AKAP12 fragment found in whole-cell
lysates were unaffected by treating the cells with isopro-
terenol for up to 30 min.
To provide insight in what region AKAP5 was docking
to AKAP12, we prepared various HA-tagged AKAP12
fragments (i.e., 1-362, 1-652, 554-938, and 840-1782),
expressed them in A431 cells, and studied AKAP5
A
AKAP12-Agarose
AKAP12(1-840)-Sepharose-4B
AKAP12(840-1782)-Sepharose-4B
Sepharose-4B
Agarose
GST-G3BP1
0       10      20     30   wash-out
2 h  
IB: GFP
IB: HA
+ Iso. Time (min)
B   IP: HA
AKAP12-GFP
HA-AKAP5
0
HA (HA-AKAP5) IgG IP
IB: AKAP5 AKAP5
IB: GST GST-G3BP1
Input
Pull down Supernatant
AKAP12-Agarose
AKAP12(1-840)-Sepharose-4B
AKAP12(840-1782)-Sepharose-4B
Figure 1 Docking of AKAP5 to full-length AKAP12 as well as to N-(1-840) and C-(840-1782) terminal fragments. A, Purified HA-tagged
AKAP12 was immobilized to agarose beads, His-tagged AKAP12 (1-840) or His-tagged AKAP12 (840-1782) were cross-linked individually to CNBr-
activated Sepharose 4B beads. Each of these bead types was incubated with either purified His-tagged AKAP5 or an equivalent amount of
purified GST-tagged G3BP1 protein, as a control. At the end of the incubation the beads were collected from the mixtures and washed. The
AKAP5 released from binding to sequences immobilized to the beads (Pull down), the AKAP5 input to the incubation (Input), and the AKAP5-
depleted supernatants of the incubation post affinity adsorption (Supernatant) were sampled and applied to SDS-PAGE, subjected to
immunoblotting and stained with anti-AKAP5 (upper panel) or anti-GST (lower panel) antibodies. B, A431 cells stably expressing GFP-tagged
AKAP12 were transiently transfected with HA-tagged AKAP5. Confluent cells were treated with 10 μM isoproterenol for 10, 20, 30 min or treated
for 30 min with isoproterenol and then washed-free of agonist for 2 h (wash-out 2 h). Whole-cell lysates were prepared and pull-downs
conducted with anti-HA antibody (targeting HA-tagged AKAP5) or control IgG. The immune complexes were subjected to SDS-PAGE, transferred
to PVDF membrane and probed with antibodies against HA tag (HA-AKAP5) or GFP (AKAP12-GFP). The results shown are taken from a single
experiment, representative of at least three separate experiments performed on separate cultures of cells.
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AKAP12 fragment and GFP-tagged AKAP5 were co-
expressed in the cells examined. Pull-downs of HA-
tagged fragments were followed by immunoblotting ana-
lysis of GFP-tagged AKAP5. Each of the AKAP12 frag-
ments displayed some capability to bind AKAP5 (Figure
2C). The capacities of the AKAP12 fragments to dock
AKAP5 varied. The fragment expressed at the highest
relative abundance in cells, AKAP (554-938) displays the
least docking capacity forA K A P 5o ft h ef r a g m e n t s
tested. AKAP5 docking to AKAP12 (1-362), the smallest
fragment tested, was prominent also (Figure 2C).
AKAP5-AKAP12 hetero-oligomerization: analysis by steric-
exclusion chromatography
We made use of wide-bore matrix steric-exclusion chro-
matography (SEC) to analyze the MW of oligomers of
purified His-tagged versions of AKAP5 and AKAP12,
both individually (Figure 3A, B; respectively), as well as
following their mixing at molar equivalence (Figure 3C).
A 60 cm column packed commercially with Sephacryl-
400 was employed. As noted earlier, AKAP5 (MW of
427 amino acid scaffold: 47.1 kDa) forms homo-oligo-
mers that have been reported to range from ~200 to
240 kDa-MW [28,29]. In the current experiments,
AKAP5 oligomers migrated with MW of 240 kDa (Fig-
ure 3A). Under these chromatography conditions,
AKAP5 oligomers do not display a sharp, symmetrical
peak. Rather, the leading edge of the AKAP5 peak is
sharp, but the tailing edge is broad, reflecting either dis-
sociation of oligomers during the steric-exclusion chro-
matography or the presence of oligomers of non-
uniform stoichiometry. A peak of monomeric AKAP5
was not apparent. The limit MW of 240 kDa suggests
1       2      3      4       5
A
75
Mr , kDa AKAP5(input)
37°C, 1 h
Sepharose-4B beads
4°C, 1 h
4°C, 17 h
IB: AKAP5
C   IP: HA
HA-AKAP12 (1-362)
HA-AKAP12 (1-652)
HA-AKAP12 (554-938)
HA-AKAP12 (840-1782)
w/o transfection
IB: AKAP5
IB: HA
250
150
100
75
105 (AKAP5-GFP)
Mr , kDa
Mr , kDa
240
160
85
80
HA-AKAP12 -+
IB: AKAP5
IB: HA
Mr , kDa
105 (AKAP5-GFP)
500 (HA-AKAP12) 
B   IP: HA
Mr , kDa
105 (AKAP5-GFP) 
240 (HA-AKAP12(840-1782)) 
Total
lysate
IB: AKAP5
IB: HA
- - 5     30 + Iso, Time (min)
-HA IgG
IP 
IB: AKAP5
IB: HA
105 (AKAP5-GFP) 
240 (HA-AKAP12(840-1782)) 
Sepharose 4B
AKAP12(840-1782)
Figure 2 Docking of AKAP5 to AKAP12. A, Purified His-tagged AKAP12 (840-1782) was cross-linked to CNBr-activated Sepharose 4B, then
incubated with purified His-tagged AKAP5 under the conditions labeled on each lane: lane 1, purified AKAP5, input; lane 2, pull-down at 37°C, 1
h; lane 3, pull-down at 4°C, 17 h; lane 4, pull-down at 4°C, 1 h; and lane 5, pull-down control, Sepharose 4B beads alone. B, A431 clones stably
expressing GFP-tagged AKAP5 were transiently transfected to express HA-tagged AKAP12 C-(840-1782) terminal fragment. Confluent cells were
treated with 10 μM isoproterenol for the indicated times. Whole-cell lysates were prepared and pull-downs performed with antibodies against
the HA tag which were covalently linked to protein A/G-agarose beads or control IgG. The immune complexes were subjected to SDS-PAGE,
transferred to PVDF membrane, and probed with antibodies against either AKAP5 or the HA tag. C, A431 cells stably expressing GFP-tagged
AKAP5 were transiently transfected with HA-tagged AKAP12 or the AKAP12 fragments listed (i.e., 1-362; 1-652; 654-938; and 840-1782). The
whole-cell lysates were prepared and pull-downs performed with antibodies against the HA tag which were covalently linked to protein A/G-
agarose beads. The immune complexes were subjected to SDS-PAGE, transferred to PVDF membrane, and probed with antibodies against either
AKAP5 or the HA tag. The results shown are taken from a single experiment, representative of at least three separate experiments performed on
separate cultures of cells.
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AKAP5.
SEC analysis of purified AKAP12 (MW of 1782 amino
acid scaffold: 191 kDa) displays a symmetrical peak with
MW of ~1.0 MDa (MDa = Mega Dalton, Figure 3B). This
higher mass MW of AKAP12 oligomer suggested the pos-
sibility of the presence of four scaffold molecules in a sin-
gle supermolecular complex. The symmetry of the
AKAP12 peak subjected to SEC likely reflects the marked
stability of the homo-oligomeric interactions of this
IB: AKAP5
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Figure 3 Steric-exclusion chromatography of AKAP5 and AKAP12 alone and in combination: identification of supermolecular AKAP5/
AKAP12 hetero-oligomers. To ascertain the possible presence of higher-order oligomers of AKAP12 and AKAP5, steric-exclusion
chromatography of purified AKAP5 and AKAP12 individually (A and B, respectively) or after incubation in combination (C) was performed on an
AKTA FPLC (GE Healthcare) fitted with a HiPrep Sephacryl S-400 High resolution 16/60 column (GE healthcare). Marker proteins mobilities were
employed to establish the MW of AKAP5-, AKAP12-, and AKAP5/AKAP12 supermolecular complexes by elution position. The A280 absorbance
was monitored in real time. Samples from each fraction were subjected to SDS-PAGE and immunoblotting and staining for the AKAP12 or
AKAP5. The results displayed are representative of at least three separate experiments performed on as many individual protein preparations.
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ciation. Although the calibration of the wide-bore Sepha-
cryl S400 matrix is reported to provide over the range of
0.02 to 8 MDa limit size, high precision assignment of
MW in this area of the chromatogram is not possible
We sought to explore if AKAP5 and AKAP12, whose
sequences are in large part natively unordered [10,22],
interact when incubated in combination. AKAP5 and
AKAP12 were incubated together at molar equivalence
(established by quantification of the His-tag) and then
subjected to SEC (Figure 3C). The results of the analysis
reveal a marked shift to higher mass of AKAP5. The
AKAP5 profile appears to display two peaks, one with
MW of ~240 kDa, as observed for the AKAP5 oligomers
a l o n e( c o m p a r eF i g u r e3 Aa n d3 C )t h eo t h e rd i s p l a y s
M Wo f1 - 2M D a( F i g u r e3 C ) .T h eA K A P 5l o w e rf i e l d
~240 kDa MW peak observed in SEC of the AKAP5/
AKAP12 mixture differs from that of AKAP5 alone in a
very important way. The AKAP5 lower field peak no
longer displays the broad tail that extended for AKAP5
alone to the limit of the AKAP5 monomer. The SEC
results suggest that in the presence of AKAP12, some
AKAP5 homo-oligomeric interactions may be stabilized.
Functional analysis of AKAP5-AKAP12 interactions
W i t ht h ee v i d e n c et h a tA K A P 5a n dA K A P 1 2f o r m i n g
hetero-oligomeric, supermolecular complexes, an
attempt was made to probe AKAP function to see if
altering the expression of one AKAP might influence
the function of the other. For AKAP5 function we made
use its well known role in mediating the ability of b-
adrenergic receptors to activate mitogen-activated pro-
tein kinases (MAPK). The MAPKs Erk1 and Erk2 (Erk1/
2) are activated in response to beta-adrenergic agonist
(e.g., isoproterenol), this activation requires AKAP5, but
not AKAP12 [13,23,24]. We measured the activation of
ERK by immunoblotting of blots from samples of
whole-cell extract subjected to SDS-polyacrylamide gel
electrophoresis with phospho- and activation-specific
antibody for Erk1/2.
HEK293 cells demonstrated a rapid, robust activation
of the MAPK cascade in response to beta-adrenergic sti-
mulation (10 μM isoproterenol), as measured by Erk1/2
activation. Within 5 min of challenge with isoproterenol,
the levels of phosphorylated, activated-Erk1/2 in cells
increased by more than 15-fold (Figure 4A). The 5-min
sampling, the earliest time point measured, displayed
the peak of the Erk1/2 activation in response to b-adre-
nergic stimulation. Erk1/2 activation thereafter declined
to 4- to 5-fold over basal within 10 min of the stimula-
tion. Erk1/2 activity remained slightly elevated for the
remaining 20 min of the time-course following isopro-
terenol (10 μM) treatment. Expression of exogenous
full-length, HA-tagged AKAP12 (HA-AKAP12) in the
HEK293
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Figure 4 Expression of AKAP12 potentiates Erk1/2 activation by beta-adrenergic agonist in HEK293 cells. The cells were transiently
transfected with HA-AKAP12 for 42 h and then changed to serum-free medium for 4 h. A, time course of ERK phosphorylation in HEK293 cells
stimulated with 10 μM isoproterenol. B, overexpression of HA-AKAP12 potentiates ERK activation in HEK293 cells stimulated in response to 10 μM
isoproterenol. C, Immunoblot analysis of expression of HA-AKAP12 using b-catenin as loading index. The blots shown are taken from a single
experiment, representative of at least three separate experiments performed on separate cultures of cells. Tabular data from separate
experiments was analyzed for variance using the Student’s “t” test for significance. * p < 0.05.
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Page 7 of 12HEK293 cells potentiated the activation of Erk1/2 in
response to isoproterenol (Figure 4B). At the 10 min
time point following stimulation with isoproterenol, the
overexpression of AKAP12 more than doubled the acti-
vation of Erk1/2 observed. The character of the time-
course of Erk1/2 activation in response to b-adrenergic
stimulation in HEK293 cells, potentiated by overexpres-
sion of AKAP12, was not changed (Figure 4B). Transfec-
tion with empty vector, in contrast, had no effect on the
Erk1/2 activation profile in response to isoproterenol
(data not shown).
Erk1/2 activation by b-adrenergic agonist in other
mammalian cell lines also is dependent upon on
AKAP5. Specific knock-down of AKAP5 expression with
siRNA reagents abolishes the ability of b-adrenergic ago-
nists to stimulate the Erk1/2 activation response [23,24].
We extended the studies from HEK293 cells to human
epidermoid carcinoma A431 cells, again probing if over-
expression of AKAP12 would impact the AKAP5-
mediated Erk1/2 activation in response to b-adrenergic
agonist. In wild-type A431 cells, isoproterenol treatment
provoked Erk1/2 activation (Figure 5A). The time-
course for Erk1/2 activation by isoproterenol in A431
cells was neither as early nor as robust as that observed
in HEK293 cells (compare Figures 4A, 5A). In A431
cells, peak activation of Erk1/2 occurred by 15 min post
isoproterenol; whereas in HEK293 cells the peak
response occurred at 5 min. In A431 cells, Erk1/2 acti-
vation in response to isoproterenol was more long-lived,
remaining robust for at least 30 min (Figure 5A);
whereas in HEK293 the early peak of activation declined
to baseline within 10 min of the initial stimulation by
isoproterenol (Figure 4A). The overexpression of HA-
tagged AKAP12 potentiated the activation of Erk1/2 in
response to isoproterenol in A431 cells (Figure 5B),
extending similar results obtained in HEK293 cells (Fig-
ure 4B). Although the time-course of the Erk1/2 poten-
tiation differs between the two cell lines, expression of
AKAP12 clearly provoked a potentiation of the Erk1/2
response, a signaling pathway mediated via AKAP5 [23].
Transfection of empty vector, in contrast, had no effects
on Erk activation (data no shown). Thus, overexpression
of AKAP12, which can form hetero-oliogomeric super-
molecular complexes with AKAP5, can influence the
function of AKAP5.
We turned our attention to exploring if overexpres-
sion of AKAP5 might impact on a function of AKAP12.
AKAP12 plays an essential role in the resensitization/
recycling of desensitized/internalized GPCRs during
recovery of the cell signaling pathway [3,7,9,10,27,33,34].
Knock-out of AKAP12 expression effectively abolishes
the receptor resensitization and recycling. We made use
of the recycling assay of desensitized/internalized b2-
adrenergic receptors as an assay for AKAP12 function.
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Page 8 of 12Recycling of the receptors can be readily detected by
ligand binding assays performed in whole cells using a
membrane-impermeable radioligand ([
3H]-CGP12177)
that reports only the cell-surface complement of beta-
adrenergic receptors [35]. Following agonist-induced
receptor internalization, AKAP12 catatlyzes the recy-
cling of the receptor back to the cell surface where they
can bind CGP12177 ligand.E x o g e n o u s ,H A - t a g g e d
AKAP5 was expressed in A431 as well as in HEK293
cells (Figure 6). The low levels of endogenous b2-adre-
nergic receptors in HEK293 cells required exogenous
expression to accommodate the recycling assay; HEK293
clones stably expressing GFP-tagged b2-adrenergic
receptors were employed for these studies. The
AKAP12-mediated recycling of internalized b2-adrener-
gic receptors was assessed in untreated cells (w/o Iso),
isoproterenol-treated cells (+Iso, 30 min), and in cells
treated with isoproterenol and then washed free of ago-
nist for 2 h (Wash-out 2 h, see Figure 6A, C). The assay
results are reported in units of “%-decline” of cell sur-
face b2AR. AKAP5 was readily expressed in the A431
and HEK293 cells, but in neither cell line was the
AKAP12-catalyzed recycling of b2-adrenergic receptors
altered by overexpression of AKAP5. The amount of
recycling of the desensitized, internalized beta2-adrener-
gic receptor at 2 h post agonist wash-out (i.e., at peak
recovery and recycling) was the same for the wild-type
cells/clones as for those overexpression AKAP5.
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This work establishes a new and important observation
in cell signaling, i.e., hetero-oligomerization of AKAPs.
Earlier AKAP5 and AKAP12 were shown to form
homo-dimers and homo-oligomers [28,29]. AKAP12
molecules were found to be so avidly bound to each
other that only the presence of the strong chaotropic
agent (e.g., 8 M urea) disrupted the oligomers to mono-
mers. The existence of the more weakly associating
homo-oligomers of AKAP5, in contrast, could be
revealed only through affinity pull-downs (e.g., co-
immunoprecipitation) and by steric-exclusion chromato-
graphy [28]. We show herein that AKAP5 and AKAP12
display the ability to hetero-oligomerize, forming very
large (1-2 MDa MW by SEC sieving) supermolecular
complexes. The presence of hetero- as well as homo-oli-
gomers suggests the possibility of the existence of
higher-order complexes among members of the wider
AKAP family. Such higher order of protein-protein
interactions may offer additional dynamic character to
signaling molecules that dock to each of these AKAP
scaffold complexes, e.g., including GPCRs [10,21,27], ser-
ine/threonine protein kinases [3,4,15,16], tyrosine
kinases [9], phosphoprotein phosphatases [7], cyclic
AMP phosphodiesterases (e.g., PDE4) [11-14], as well as
other docking proteins [3,4,36].
Another new dimension of AKAP biology is that the
docking of the mobile AKAP12 to the AKAP5 bound to
the cell membrane is shown to be sensitive to activation
of the cyclic AMP pathway, provoking an intimately
orchestrated spatio-temporal association of these two
scaffolds. Uncovering the functional implications of
AKAP-AKAP hetero-oligomerization, if any, was an
important task. Overexpression of AKAP12 is shown to
markedly potentiate the ability of AKAP5 to mediate the
b-adrenergic agonist regulation of Erk1/2 activation. In
both HEK293 and A431 cells, overexpression of
AKAP12 potentiated AKAP5-mediated signaling. The
increased AKAP12, if docking to AKAP5, might recruit
additional signaling molecules to the locale membrane
microenvironment. These molecules could stabilize the
beta-adrenergic stimulus and thereby potentiate the acti-
vation of Erk1/2. On the other hand, we did not see any
detectable effect of AKAP5 overexpression on AKAP12-
mediated signaling read-outs, e.g., beta-adrenergic recep-
tor resensitization and recycling. This observation con-
firms our earlier findings [23], that AKAP5 was not
necessary for beta-adrenergic receptor resensitization/
recycling. Knock-down of AKAP5 did not significantly
affect AKAP12-mediated receptor recycling. AKAP5
localizes strictly to the cell membrane, which would
have a nearly infinite capacity to bind this scaffold, even
when overexpressed. In this feature, AKAP5 is
fundamentally unlike AKAP12 which can be found
throughout the cytoplasm and dynamically docks to the
cell membrane.
Full-length AKAP12 docks to the membrane-bound
AKAP5. Full-length AKAP12 as well as the large N- and
C- terminal fragments of AKAP12 displayed the capacity
to dock to AKAP5. A large central region (556-938) of
AKAP12, in contrast, displayed the least capacity to
dock AKAP5. This same region of AKAP12 was shown
earlier to be essential for AKAP12 function, itself phos-
phorylated by protein kinase A in response to beta-adre-
nergic agonist treatment [27]. Further, this region
harbors the Receptor-Binding Domain (RBD), which
interacts reversibly with b-adrenergic receptors (and
perhaps other GPCRs) during the desensitization/inter-
nalization and resensitization/recycling of the GPCR to
the cell membrane. A domain with analogy to the RBD,
which also is a substrate for protein kinase A-catalyzed
phosphorylation, can be discerned in AKAP5; both
AKAP5 and AKAP12 dock b-adrenergic receptors
[10,22].
Uncovering the molecular basis for AKAP oligomeri-
zation remains an important target. The primary
sequences of both AKAP5 and AKAP12, although
clearly replete in docking sites for numerous proteins,
are predicted to be largely “natively-unordered” (Figure
7). FOLDindex
© predicts intrinsic unfolding based upon
the average residue hydrophobicity and the net charge
in the primary sequence of a protein [37,38]. By FOL-
Dindex
©, human AKAP12 is predicted to be >90%
natively unordered, whereas AKAP5 is predicted to be
>80% natively unordered. Intuitively, we might suspect
that a high content of unordered structure would pre-
clude or at least limit the function of a scaffold (i.e.,
unordered sequences would seem to afford fewer dock-
ing sites for the large number of protein ligands inter-
acting with AKAP12) [10,22,26]. Not only AKAP5 and
AKAP12, but also MAP2 and other AKAP family mem-
bers, by this same analysis, appear to be largely natively
unordered. AKAP1, in contrast to AKAP12, AKAP5, or
MAP2, does display significant regions of ordered struc-
ture (Figure 7). By analogy, Dishevelled-1, -2, and -3, are
scaffold proteins that function in Wnt signaling. Each of
these Dishevelleds is predicted by FOLDindex to possess
>85% ordered structure [39,40], including the presence
of DIX, PDZ, DEP domains and sites for a multitude of
docking partners [39].
We speculate that the “natively unordered” primary
sequence of AKAPs, like AKAP5 and AKAP12, consti-
tute docking sites quite different from highly-structured
domains such as DIX, PDZ, and DEP. The high content
of natively unordered sequence (and prolyl residues)
must provide some additional “flexibility” or benefit that
Gao et al. Journal of Molecular Signaling 2011, 6:8
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sequence by the FOLDindex
©. AKAP12, as noted above,
displays a Receptor-Binding Domain for GPCRs [27],
several docking sites for protein kinase C [33,34], and
for PDE4 [14] in just the very regions that are reported
to be largely “natively unordered”. More detailed analy-
sis of sites of homo-oligomerization as well as of dock-
ing sites involved in AKAP hetero-oligomerization is
essential. Establishing the basis for the oligomerization
of AKAP monomers to higher order, supermolecular
hetero-oligomers in response to activation of beta-adre-
nergic pathway will be required to more fully under-
stand the biology of AKAP scaffolds in cell signaling.
Conclusion
The current investigation demonstrates for the first time
that members of the AKAP family, AKAP5 and
AKAP12, can form not only homo-oligomers, but also
hetero-oligomers. The hetero-oligomeric AKAP are
higher-order supermolecular complexes. The intracellu-
lar ratio between AKAP5/AKAP12 can influence func-
tions of AKAPs. Thus, the existence of large,
supermolecular hetero-oligomers of AKAPs adds a new
dimension to the possibilities for docking of one AKAP
with another member of the AKAP family in novel and
functionally important ways.
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The primary sequences of human AKAP5, AKAP12, and several other members of the AKAP family were analyzed for natively ordered structure
by application of the FOLDindex
©. The sequences are displayed from N-terminus to C-terminus (left to right) for four of the AKAP sequences
selected. The regions below the horizontal midline, filled in with red, are predicted to be natively unfolded based upon primary sequence
information alone. The regions above the horizontal midline, filled in with green, are predicted to be natively folded, based upon primary
sequence.
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